Marinus Pharma上调了23财年预期：ZTALMY收入从1500万美元到1700万美元增加到1700万美元到1850万美元，BARDA收入从800万美元到1100万美元增加到1100万美元到1200万美元

2023-08-10 19:08

GAAP Operating Expense: The Company now expects GAAP operating expenses, inclusive of G&A and R&D, to be in the range of $160 to $165 million, of which the Company expects stock-based compensation to be approximately $15 million; this represents a decrease from the prior guidance range of $165 to $175 million
Expect that cash, cash equivalents, and short-term investments of $175.3 million as of June 30, 2023, will be sufficient to fund the Company's operating expenses, capital expenditure requirements, and maintain the minimum cash balance of $15 million required under the Company's debt facility into the second half of 2024.